Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Systemic sclerosis
If a patient with limited scleroderma presents with the three active domains including skin thickening, inflammatory joint pain, and ILD would you consider starting Actemra?
Related Questions
If a patient has progression of scleroderma-ILD on MMF alone, and you are planning to start tocilizumab, would you continue MMF at a lower dose to maintain skin softening?
What are some important considerations for use of ACE inhibition in scleroderma renal crisis patients who require dialysis?
How would you approach a patient with anti-scl70 ab positive sine scleroderma complicated by ILD who also has seropositive RA with active arthritis?
Would you continue belimumab in high risk lupus patients with overlapping scleroderma features with ILD who become pregnant and who are already on HCQ and azathioprine?
What would be your recommendation for treatment of worsening lung disease in a patient with long-standing scleroderma after long-term mycophenolate therapy which is no longer an option due to side effect/intolerance?
Would you consider altering immunosuppression in a patient with systemic sclerosis (already on systemic immunosuppression for interstitial lung disease) who has more recently been noted to have LV diastolic dysfunction with some reduction in EF in the absence of other worsening symptoms?
How do you manage trigeminal sensory neuropathy in a patient with systemic sclerosis?
How do you approach the significance of +RNP III antibody in a patient with positive ANA but no other signs or symptoms of systemic sclerosis?
How do you envision incorporating CAR-T therapy into your clinical practice?
Are there situations in which you treat calcinosis cutis that is not symptomatic for the patient?
